Russell Investments Group Ltd. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,505,319 shares of the company’s stock after selling 170,181 shares during the quarter. Johnson & Johnson accounts for 0.6% of Russell Investments Group Ltd.’s portfolio, making the stock its 19th largest holding. Russell Investments Group Ltd.’s holdings in Johnson & Johnson were worth $664,052,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the company. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $28,000. Matrix Trust Co boosted its position in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Navigoe LLC boosted its position in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after acquiring an additional 55 shares in the last quarter. Montgomery Financial Services LLC bought a new position in Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. bought a new position in Johnson & Johnson in the third quarter valued at approximately $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
JNJ has been the subject of several recent analyst reports. Erste Group Bank cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Citigroup lifted their price target on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. The Goldman Sachs Group reissued a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Royal Bank Of Canada dropped their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $275.92.
View Our Latest Research Report on JNJ
Johnson & Johnson Trading Up 1.2%
Shares of Johnson & Johnson stock opened at $283.69 on Friday. The firm has a market capitalization of $682.93 billion, a PE ratio of 42.98, a price-to-earnings-growth ratio of 2.77 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm’s 50 day moving average is $266.83 and its 200 day moving average is $249.54. Johnson & Johnson has a 1 year low of $193.45 and a 1 year high of $286.08.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is 81.21%.
Latest Johnson & Johnson News
Investors following JNJ have been watching these news items:
- Neutral Sentiment: State Street’s Health Care SPDR added J&J shares on Nov. 10 as part of a broader increase across all of the fund’s holdings. The purchase provides an institutional-demand datapoint but was not specific to J&J. State Street Health Care SPDR adds Johnson & Johnson
- Negative Sentiment: A Massachusetts jury awarded $3.3 million to the family of a woman who developed mesothelioma after using J&J talc-based baby powder. The award adds to ongoing talc-related litigation exposure. Massachusetts woman’s family awarded $3.3 million against Johnson & Johnson
- Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of J&J investors. The announcement does not establish wrongdoing or the outcome of any claims, but adds another legal headline for investors to monitor. Pomerantz law firm investigates claims on behalf of J&J investors
Insider Buying and Selling at Johnson & Johnson
In related news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
See Also
- Five stocks we like better than Johnson & Johnson
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
